Life Science Investing Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition
Life Science Investing Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting & Exposition
Life Science Investing Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg To Be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Life Science Investing Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Life Science Investing Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Life Science Investing Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
Life Science Investing Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology Annual Meeting
Life Science Investing Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Life Science Investing Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress
Life Science Investing Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Life Science Investing Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nine Mile Metals Announces Certified High-Grade Assay Results up to 15.21% Copper from the Wedge Project, Bathurst, New Brunswick
